|Historically, the roots of Zedira go back to Prof. Lothar Fuchsbauer’s work on microbial transglutaminase at the University of Applied Sciences in Darmstadt, Germany, during the 1990s. At that time, he discovered together with his PhD student Ralf Pasternack, that microbial transglutaminase derived from Streptomyces species is produced as an inactive pro-enzyme that is activated by the cleavage of a propeptide. The enzyme is well known as a “biological glue” widely used in food processing.
In 1999 the start-up N-Zyme BioTec was founded by Lothar and Ralf along with Prof. H.G. Gassen (Darmstadt University) and Dr. J. Klein (Doehler Group) to target novel applications of microbial transglutaminase. One year later Martin Hils joined the company bringing along his expertise in molecular biology and recombinant protein production.
Today, recombinant microbial transglutaminase (T001) is one of the most important products in our portfolio. The highly active and purified transglutaminase is especially useful for site-specific protein modification.
In the ensuing years the business focus has shifted more and more towards human transglutaminases and their role in various diseases, including the development of small molecule blockers of transglutaminases. Drug discovery requires funding and therefore investors. Consequently, in 2007 Martin and Ralf decided to establish a pharmaceutical company, which they named Zedira. The company started with the aim of generating transglutaminaserelated products geared towards celiac disease.
|Over the last 18 years we have developed many products for our internal R&D. However, we have also decided to market these products, in order to fulfill our mission: to catalyze research in the transglutaminase field, both in academia and in industry, by providing reliable, firstrate products.
Be assured that we will do our very best to support you and your essential work. This is not just a stereotypical marketing platitude. We sincerely wish to communicate directly with you – so whenever you have questions concerning our products, or if you need research tools thus far not implemented in our portfolio, please do not hesitate to contact us.
Further, we provide an independent communication platform entitled “Transglutaminase Blog”. We invite scientists renowned in their respective field to write short articles about their work. Since the transglutaminase cosmos is extremely broad, we expect more exciting articles in the coming years.
What will the future for transglutaminases look like? Actually, we see a growing interest of the pharmaceutical industry in transglutaminases. In case this interest turns out to be sustainable, it is going to boost the research in academia and industry. We are confident that there is a bright future for the whole transglutaminase community.
Zedira is committed to accompany the endeavor.
On behalf of the entire Zedira team
Ralf Pasternack and Martin Hils
|Download a digital version of our Transglutaminase Speciality Reagents catalogue, 2017 edition.|